Wong et al. [121] presented the clinical cases of three patients with T1D and comorbid obesity who exhibited reduced insulin requirements and remarkable weight loss after the initiation of GLP-1 RA and pramlintide (amylin analog) combination therapy (in addition to intensive lifestyle modifications). Here, GLP1R is linked to obesity disorder.